N EREN1, S BEK1
1Kocaeli University Hospital, Kocaeli, Turkey
Aim: Polysaccharide pneumococcal vaccine (PPSV23) has been shown to reduce the incidence of pneumonia in hemodialysis (HD) patients. The aim of this study was to investigate the rate of vaccination with pneumococcal vaccine and the factors that may affect it.
Background: Polysaccharide pneumococcal vaccine (PPSV23) has been shown to significantly reduce the incidence of pneumonia. This study aimed to investigate the rates of vaccination in hemodialysis patients and the factors that may affect it with a questionnaire.
Methods: In the Kocaeli province, 683 HD patients from 7 centers were included in the study. A questionnaire of 29 questions were conducted.
Results: The median age of the patients (54.8% male, 45.2% female) was 62 (15-94) years, with a median dialysis time of 50 months for HD patients. 47.3% of the patients had influenza vaccine and 18.8% had pneumococcal vaccine. There was no difference in rates of annual influenza and pneumococcal vaccination in women and men, (p = 0.917 and p=0.119). 23% of patients with hepatitis B vaccine had a pneumococcal vaccine while 12% of patients without hepatitis B vaccine had a pneumococcal vaccine, which was statistically significant (p = 0.001). Median dialysis duration was significantly longer for who had annual influenza(p = 0.001) and pneumococcal vaccine (p = 0.018) than those who did not have.
Conclusion: In our study, influenza and pneumococcal immunization rates were lower than in US data and patients with hepatitis B vaccination were more likely to have also pneumococcal vaccine. Longer dialysis period increase the risk of both influenza and pneumococcal infections and more efforts should be done to increase the rates of vaccination in HD.
We are working together as assistant professor in Kocaeli University Hospital. I,Sibel Gokcay Bek, will be working in Sydney University , Nephrology Departmant as ISN fellow for one year.